Kuraray to Release SCAPOVA™ AS PVA Microcarrier
Kuraray Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President: Hitoshi Kawahara) will release SCAPOVA™ AS, a new variant in the SCAPOVA™ PVA microcarrier series, on December 1, 2025, within Japan.
SCAPOVA™ AS is an uncoated type featuring a specially treated PVA hydrogel surface. Users can easily customize the surface by coating preferred adhesion molecules—such as ECM proteins (vitronectin, fibronectin, laminin), laminin-derived products like iMatrix-511 (Matrixome), synthetic peptides like Synthemax® II (Corning), as well as poly-L-lysine or collagen—to optimize adhesion for specific cell types. This flexibility expands the range of cells that can be cultured, including applications such as iPS cell culture using iMatrix-511, and other cell types that do not thrive on collagen-coated carriers.
Because SCAPOVA™ AS is Animal Origin Free (AOF), it enables xeno-free and serum-free culture systems. It addresses the growing demand for materials free from animal-derived components in regenerative medicine, where high safety standards are essential.
SCAPOVA™ AS will also be available in the U.S. market together with SCAPOVA™ CL.
For details on specifications and distributions, please contact us.
About SCAPOVA™
Product Lineup
- SCAPOVA™ CL: Collagen-coated type
- SCAPOVA™ AS: Uncoated type
Product Website https://www.kuraray.co.jp/microcarriers/
Contact Life Innovation Business Promotion Department Contact.LIPG@kuraray.com